Beyond the Pill: Psychosocial and Behavioural Predictors of ART Non-Adherence Following the Single-Tablet Regimen Transition in Yaoundé, Cameroon

Download Article

DOI: 10.21522/TIJPH.2013.14.01.Art001

Authors : Mbohli Semirnyuy Sharon Lum, Djenabou Amadou, Pefura Yone Eric Walter

Abstract:

Achieving the UNAIDS 95-95-95 targets depends on optimal adherence to antiretroviral therapy (ART). While Cameroon transitioned to simplified Dolutegravir-based Single-Tablet Regimens (STR), the impact on adherence relative to Multiple-Tablet Regimens (MTR) remains to be elucidated. This hospital-based cross-sectional study among 680 participants at Yaoundé Jamot Hospital quantified adherence using a modified CPCRA 7-day recall and CASE Adherence Index. Results indicated an optimal adherence prevalence of 79.7% (95% CI: 76.4–82.7%) for the 7-day recall and 80.9% for the CASE Index. No significant difference in adherence was observed between STR and MTR users (p = 0.494). Multivariable modified Poisson regression revealed that lack of family support was the strongest predictor of non-adherence (aPR: 1.407, 95% CI: 1.203–1.646; p < 0.001). Other significant factors included depressive symptoms (aPR: 1.257, 95% CI: 1.036–1.525) and risky alcohol consumption (aPR: 1.158, 95% CI: 1.096–1.224). These findings suggest that in the era of simplified regimens, adherence is driven primarily by psychosocial and behavioural determinants rather than physical drug complexity. To bridge the final 20% gap, interventions must prioritize family support systems and mental health screening alongside pharmacological simplification.

References:

[1].   UNAIDS, 2022, Global HIV & AIDS statistics. UNAIDS Reports, Geneva. https://www.unaids.org/en/resources/documents/2022/2022_Global_AIDS_Update.

[2].   Bangsberg, D. R., et al., 2001, Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS, 15(9), 1181–1183, https://doi.org/10.1097/00002030-200106150-00015

[3].   Fonsah, J. Y., et al., 2017, Adherence to Antiretroviral Therapy (ART) in Yaoundé, Cameroon: Association with Opportunistic Infections, Depression, ART Regimen, and Side Effects. PLoS One, 12(1), e0170893, https://doi.org/10.1371/journal.pone.0170893.

[4].   Pefura-Yone, E. W., et al., 2013, Non-adherence to antiretroviral therapy in Yaounde: Prevalence, determinants and the concordance of two screening criteria. Journal of Infection and Public Health, 6(4), 307–315, https://doi.org/10.1016/j.jiph.2013.02.003.

[5].   World Health Organization, 2019, Update of recommendations on first- and second-line antiretroviral regimens. WHO Guidelines, Geneva.

[6].   Kounafack, et al., 2019, Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1. New England Journal of Medicine, 381(9), 816–826, https://doi.org/10.1056/NEJMoa1904340.

[7].   Venter, W. D. F., et al., 2019, Dolutegravir-based ART for HIV treatment: Evidence and implications. Lancet HIV, 6(7), e430–e442.

[8].   Mbengue, M. A. S., et al., 2019, Prevalence and determinants of adherence to antiretroviral treatment among HIV patients on first-line regimen: a cross-sectional study in Dakar, Senegal. Pan African Medical Journal, 33(95), https://doi.org/10.11604/pamj.2019.33.95.17248.

[9].   Tchokonte-Nana, V., et al., 2021, The effectiveness of SMS reminders to improve ART adherence in Cameroon. Pan African Medical Journal, 38(6), 307.

[10].  Diyir, E. B., et al., 2025, HIV/AIDS and Adolescent Adherence to Antiretroviral Therapy: A Cross-Sectional Study of Adolescents in the Bamenda Health Districts, Cameroon. Journal of Biosciences and Medicines, 13(11), 237–266, https://doi.org/10.4236/jbm.2025.1311017.

[11].  Chesney, M. A., et al., 2000, Adherence to HIV combination therapy. Social Science & Medicine, 50(11), 1599–1605, https://doi.org/10.1016/S0277-9536(99)00468-2.

[12].  Rostant Pokam Djoko, G., et al., 2024, Factors influencing adherence to antiretroviral treatment among people living with HIV aged 15–60 years at Cité des Palmiers District Hospital, Cameroon. Global Health Economics and Sustainability, 3(1), 118, https://doi.org/10.36922/ghes.4077.

[13].  Mekolle, J. E., et al., 2023, Political instability and HIV/AIDS response in the south west and north west regions of Cameroon: a qualitative study. BMC Public Health, 23(1), 2155, https://doi.org/10.1186/s12889-023-16994-w.

[14].  Mbuagbaw, L., et al., 2012, Trends and determining factors associated with adherence to antiretroviral therapy (ART) in Cameroon: a systematic review and analysis of the CAMPS trial. AIDS Research and Therapy, 9(1), 37, https://doi.org/10.1186/1742-6405-9-37.

[15].  Cameroon Demographic and Health Survey (DHS), 2018, HIV prevalence statistics. DHS Program, Rockville, MD.

[16].  Mannheimer, S. B., et al., 2006, The CASE adherence index: A novel method for measuring adherence to antiretroviral therapy. AIDS Care, 18(7), 853–861, https://doi.org/10.1080/09540120500465160.

[17].  Chesney, M. A., et al., 2000, Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence Instruments. AIDS Care, 12(3), 255–266, https://doi.org/10.1080/09540120050042891.

[18].  Mannheimer, S. B., et al., 2006, The CASE adherence index: A novel method for measuring adherence to antiretroviral therapy. AIDS Care, 18(7), 853–861, https://doi.org/10.1080/09540120500465160.

[19].  Kroenke, K., et al., 2003, The Patient Health Questionnaire-2. Medical Care, 41(11), 1284–1292, https://doi.org/10.1097/01.MLR.0000093487.78664.3C.

[20].  Bush, K., et al., 1998, The AUDIT Alcohol Consumption Questions (AUDIT-C): An Effective Brief Screening Test for Problem Drinking. Archives of Internal Medicine, 158(16), 1789, https://doi.org/10.1001/archinte.158.16.1789.

[21].  Byrd, K. K., et al., 2019, Antiretroviral adherence level necessary for HIV viral suppression using real-world data. JAIDS Journal of Acquired Immune Deficiency Syndromes, 82(3), 245–251, https://doi.org/10.1097/QAI.0000000000002142.

[22].  Clay, P. G., et al., 2018, A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV. AIDS Research and Therapy, 15(1), 17, https://doi.org/10.1186/s12981-018-0204-0.

[23].  Altice, F., et al., 2019, Adherence to HIV treatment regimens: systematic literature review and meta-analysis. Patient Preference and Adherence, 13, 475–490, https://doi.org/10.2147/PPA.S192735.

[24].  Braitstein, P., et al., 2008, Gender and the Use of Antiretroviral Treatment in Resource-Constrained Settings: Findings from a Multicenter Collaboration. Journal of Women's Health, 17(1), 47–55, https://doi.org/10.1089/jwh.2007.0353.

[25].  Mabou, G. T., et al., 2025, Factors associated with HIV status non-disclosure among people entering care at IeDEA sites in Cameroon: a cross-sectional study. AIDS Research and Therapy, 22(1), 100, https://doi.org/10.1186/s12981-025-00765-1.

[26].  Kagee, A., et al., 2011, Structural barriers to ART adherence in Southern Africa: Challenges and potential ways forward. Global Public Health, 6(1), 83–97, https://doi.org/10.1080/17441691003796387.

[27].  Constantin, T., et al., 2020, Risky Behaviors among HIV Serodiscordant and Seroconcordant Couples in Yaounde-Cameroon. International Journal of Virology and AIDS, 7(1), https://doi.org/10.23937/2469-567X/1510062.

[28].  Kalichman, S. C., et al., 2012, Alcohol and Adherence to Antiretroviral Medications: Interactive Toxicity Beliefs Among People Living With HIV. Journal of the Association of Nurses in AIDS Care, 23(6), 511–520, https://doi.org/10.1016/j.jana.2011.11.005.